“. . . Alzheimer’s patients have been observed to have a higher degree of pineal gland calcification than patients with other types of dementia, and sleep disturbances have been identified as a primary cause of Alzheimer’s disease pathogenesis . . .” C Sarich
Alzheimer’s disease is running rampant throughout the modern world now, but even with pharmaceutical companies spending billions on drugs to ‘cure’ it, they have failed miserably. While the use of coconut oil for Alzheimer’s disease is proving beyond beneficial, the answer to really treating this disease may lie in the pineal gland and the decalcification of one of the most important elements of the endocrine system.
For the past few decades, research into treating Alzheimer’s disease has been relegated to an assumption: that it is caused by the lack of the neurotransmitter, acetylcholine. In fact, most pharmaceuticals made to treat Alzheimer’s patients are acetylcholinesterase inhibitors (drugs that inhibit the enzyme that breaks this neurotransmitter down.)
Big Pharma Fails to Treat Alzheimer’s
These drugs have produced only palliative results, if any, and many of them cause seizures or other neurological issues in the patients who take them. As Sayer Ji from GreenMedInfo so convincingly points out, Alzheimer’s drugs are nothing but patented xenobiotic chemicals, completely alien to human physiology. So – if this is the case, it makes sense to look deeper into the causes of such a prevalent disease which is said to be ‘bigger than cancer’ for the pharmaceutical markets.
Despite failed trials, Big Pharma continues to invest heavily in ‘cures’ that may not do anything but worsen the disease.
For instance, trials of Eli Lilly’s gamma-secretase inhibitor, semagacestat (LY450139), were halted due to below par results. Later, despite reports that results of solanezumab, a neuroprotector that binds to plaque and inhibits its formation, were positive, the company said that it was not going to the FDA for approval, but will conduct a third Phase III trial. The company has already failed three times at creating a “inhibitor that would address this disease effectively. Continue reading